Jörn Rüssel

469 total citations
21 papers, 317 citations indexed

About

Jörn Rüssel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Jörn Rüssel has authored 21 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Jörn Rüssel's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Jörn Rüssel is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Jörn Rüssel collaborates with scholars based in Germany, Switzerland and Poland. Jörn Rüssel's co-authors include Joachim G.J.V. Aerts, Manlio Mencoboni, Federica Grosso, Jan P. van Meerbeeck, S. Cedrés, Rodryg Ramlau, David Planchard, Maciej Krzakowski, Lucio Crinò and Antonio Chella and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Jörn Rüssel

18 papers receiving 308 citations

Peers

Jörn Rüssel
Jörn Rüssel
Citations per year, relative to Jörn Rüssel Jörn Rüssel (= 1×) peers Nausicaa Malissen

Countries citing papers authored by Jörn Rüssel

Since Specialization
Citations

This map shows the geographic impact of Jörn Rüssel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörn Rüssel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörn Rüssel more than expected).

Fields of papers citing papers by Jörn Rüssel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörn Rüssel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörn Rüssel. The network helps show where Jörn Rüssel may publish in the future.

Co-authorship network of co-authors of Jörn Rüssel

This figure shows the co-authorship network connecting the top 25 collaborators of Jörn Rüssel. A scholar is included among the top collaborators of Jörn Rüssel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörn Rüssel. Jörn Rüssel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thiele, Benjamin, Alexander Stein, Christoph Schultheiß, et al.. (2024). Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial. Clinical Colorectal Cancer. 24(1). 11–17. 2 indexed citations
2.
Schmoll, Hans‐Joachim, Lars H. Lindner, Peter Reichardt, et al.. (2020). Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma. JAMA Oncology. 7(2). 255–255. 22 indexed citations
3.
Ceresoli, Giovanni Luca, Joachim G.J.V. Aerts, Rafał Dziadziuszko, et al.. (2019). Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. The Lancet Oncology. 20(12). 1702–1709. 107 indexed citations
5.
Rüssel, Jörn, et al.. (2019). Kardiotoxizität onkologischer Therapien (2): KHK, Vitien, Arrhythmien, Hypertonie und Thrombosen. Deutsches Ärzteblatt. 1 indexed citations
6.
Rüssel, Jörn, et al.. (2018). Kardiotoxizität onkologischer Therapien (1): Myokardiale Dysfunktion und Herzinsuffizienz. Deutsches Ärzteblatt. 2 indexed citations
7.
Schmoll, Hans‐Joachim, Benjamin Garlipp, Christian Junghanß, et al.. (2017). FOLFOX/Bevacizumab +/− Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis. Annals of Oncology. 28. iii152–iii152. 1 indexed citations
8.
Schmoll, Hans‐Joachim, Benjamin Garlipp, Christian Junghanß, et al.. (2017). CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209).. Journal of Clinical Oncology. 35(4_suppl). 658–658. 7 indexed citations
9.
Schmoll, Hans‐Joachim, Benjamin Garlipp, Christian Junghanß, et al.. (2017). “CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.. Journal of Clinical Oncology. 35(15_suppl). 3533–3533. 15 indexed citations
10.
Quidde, Julia, Hans‐Joachim Schmoll, Benjamin Garlipp, et al.. (2017). Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial.. Journal of Clinical Oncology. 35(15_suppl). 3544–3544. 1 indexed citations
12.
Schmoll, Hans‐Joachim, Jörn Rüssel, Peter Reichardt, et al.. (2016). Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.. Journal of Clinical Oncology. 34(15_suppl). 11004–11004. 3 indexed citations
13.
Jordan, Karin, et al.. (2016). Diagnostic work-up for the detection of malnutrition in hospitalized cancer patients. The Journal of Community and Supportive Oncology. 14(4). 155–161. 4 indexed citations
14.
Jordan, Karin, Franziska Jahn, Berit Jordan, et al.. (2015). Trabectedin: Supportive care strategies and safety profile. Critical Reviews in Oncology/Hematology. 94(3). 279–290. 10 indexed citations
15.
Bergmann, Lothar, Luise Maute, Gerhard Heil, et al.. (2014). A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. European Journal of Cancer. 51(1). 27–36. 51 indexed citations
16.
Raue, F., Martin Faßnacht, Dagmar Führer, et al.. (2014). Management des fortgeschrittenen medullären Schilddrüsenkarzinoms. Der Onkologe. 20(6). 591–598. 2 indexed citations
17.
Richly, Heike, Luise Maute, Gerhard Heil, et al.. (2013). Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.. Journal of Clinical Oncology. 31(15_suppl). 4035–4035. 7 indexed citations
18.
Rüssel, Jörn, Alexander Stein, Curd Behrmann, et al.. (2011). Inflammatory Lesions of the Peritoneum Mimic Carcinomatosis After Treatment With Intravenous Chemotherapy and Intraperitoneal Catumaxomab. Journal of Clinical Oncology. 29(22). e644–e646. 7 indexed citations
20.
Rüssel, Jörn. (2008). The current management of septic shock.. PubMed. 99(5). 431–58. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026